Johnson & Johnson sales exceeded expectations, rising more than 1% in pre-market trading.

Johnson & Johnson's quarterly sales exceeded Wall Street expectations and raised its full-year performance outlook, despite facing threats of tariffs and drug pricing controls, showing confidence. Johnson & Johnson CFO Joe Wolk said that the delay in implementing tariffs shows that "people realize that biopharmaceutical manufacturing facilities cannot be built overnight." The company raised the midpoint of its 2025 revenue forecast and also increased the midpoint of its full-year adjusted earnings outlook, with sales reaching $23.7 billion this quarter, surpassing analysts' average expectations. Johnson & Johnson's second-quarter sales were $23.74 billion, surpassing the estimated $22.84 billion. Adjusted earnings per share were $2.77 in the second quarter. Sales of STELARA in the second quarter were $1.65 billion, missing the estimated $1.77 billion. Johnson & Johnson expects full-year sales of $93.2 billion to $93.6 billion, up from the previous estimate of $91 billion to $91.8 billion. Johnson & Johnson expects full-year adjusted earnings per share to be between $10.80 and $10.90, up from the previous estimate of $10.50 to $10.70.